Sandoz’s Biosimilar Filgrastim Sails Through FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Extensive European experience helps reassure Oncologic Drugs Advisory Committee about safety and similarity to Amgen’s Neupogen.